Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.
High comorbidity burden was associated with worse survival outcomes in patients with chronic lymphocytic leukemia who were treated with ibrutinib.
A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.
Prolonged postoperative and radiation intervals were associated with worse survival outcomes in patients with head and neck cancer.
The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.
Age and pretreatment comorbidities were shown to impact survival outcomes in patients with locally advanced laryngeal cancer.
Researchers clarified the role of miR-125a-5p in bladder cancer, showing that it inhibits bladder cancer progression by targeting oncogene FUT4.
A retrospective study found EGFR and HER2 overexpression associated with clinical features, such as tumor stage and tumor recurrence, in bladder cancer tissue.
After antibiotic treatment during allogeneic hematopoietic stem cell transplantation, fecal transplantation was shown to restore patients’ gut microbiota.
A flat-dosing schedule of nivolumab (480 mg every 4 weeks) showed pharmacologic activity and safety similar to other schedules.
In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.